BIOGEN HIRULOG AND CD4 DRY HOLES EXHIBIT IMPORTANCE OF OUTSOURCING STRATEGY, EXEC SAYS: MORE COSTLY IN SHORT-TERM BUT PERMITS SUSTAINABLE MULTIPLE PROJECTS
Executive Summary
Biogen's decision to use a "virtual" drug development approach in the early 1990s has helped it to weather two significant dry holes and to maintain a degree of stability, Associate Director of Medical Operations Gunther Winkler, PhD, indicated in a presentation at an April 20-21 meeting on "Virtual Corporation Strategies" in Boston.